The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| EYPT | +6.51% | +149.73% | +20.09% | -64% |
| S&P | +14.5% | +93.32% | +14.09% | +402% |
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.
The company reported positive trial data for its lead therapy to treat two different eye conditions.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $5.33M | -43.7% |
| Gross Profit | $4.63M | -42.7% |
| Gross Margin | 86.82% | 1.6% |
| Market Cap | $647.52M | 42.9% |
| Market Cap / Employee | $3.92M | 0.0% |
| Employees | 165 | 36.4% |
| Net Income | -$59.43M | -92.8% |
| EBITDA | -$61.69M | -80.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $71.14M | -21.6% |
| Accounts Receivable | $0.63M | -54.5% |
| Inventory | 2.7 | -27.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $21.82M | -1.6% |
| Short Term Debt | $0.00M | -100.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -56.09% | -21.4% |
| Return On Invested Capital | -48.71% | 12.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$63.81M | -202.7% |
| Operating Free Cash Flow | -$62.59M | -210.2% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.96 | 1.82 | 1.10 | 2.17 | 24.96% |
| Price to Sales | 9.52 | 11.11 | 6.75 | 12.68 | 38.02% |
| Price to Tangible Book Value | 1.96 | 1.82 | 1.10 | 2.17 | 24.96% |
| Enterprise Value to EBITDA | -6.32 | -2.97 | -1.74 | -6.87 | 14.11% |
| Return on Equity | -74.7% | -43.4% | -53.5% | -74.0% | 21.62% |
| Total Debt | $23.21M | $23.11M | $24.08M | $21.82M | -6.35% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
